/
IOVA
$4.21-$0.04 (-0.94%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.9B
447M shares
52-week range
$1.67 – $5.63
64% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-21.81
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.2M | $164.1M | $263.5M |
| Cost of revenue | $956.0K | $8.1M | $0 | $0 | $0 | $10.8M | $124.0M | $7.3M |
| Gross profit | −$956.0K | −$8.1M | $0 | $0 | $0 | −$9.6M | $40.1M | $256.2M |
| Gross margin | — | — | — | — | — | -804.5% | 24.4% | 97.2% |
| R&D | $99.8M | $166.0M | $201.7M | $259.0M | $294.8M | $344.1M | $282.3M | $300.3M |
| Operating income | −$128.3M | −$206.9M | −$261.9M | −$342.7M | −$398.9M | −$460.6M | −$395.3M | −$403.4M |
| EBITDA | −$122.6M | −$189.4M | −$260.8M | −$328.3M | −$371.8M | −$414.4M | −$331.4M | −$357.1M |
| Net income | −$123.6M | −$197.6M | −$259.6M | −$342.3M | −$395.9M | −$444.0M | −$372.2M | −$391.0M |
| Net margin | — | — | — | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (diluted) | -1.27 | -1.50 | -1.88 | -2.23 | -2.49 | -1.89 | -1.28 | -1.09 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $362M | $-0.55 | $-0.64–$-0.35 | 6 |
| 2027 | $496M | $-0.31 | $-0.36–$-0.24 | 6 |
| 2028 | $740M | $0.00 | $-0.01–$0.01 | 5 |
| 2029 | $987M | $0.21 | $0.20–$0.23 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$4.14
Price
$4.21
Implied downside
-2%
Peer comparison
Iovance Biotherapeutics, Inc. Common Stock
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
www.iovance.com- Employees
- 975
- IPO / List date
- May 26, 2010
- HQ
- SAN CARLOS, CA
Held by traders on TradeandTell
No one on the platform currently holds IOVA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 651,000 | $1.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IOVA yet.
